Piracetam for reducing the incidence of painful sickle cell disease crises

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 2, 2016, Pages

  Al Hajeri, Amani ^a   Fedorowicz, Zbys ^b  

^a Ministry of Health   (Bahrain)

^b Bahrain Branch ^*  (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; PIRACETAM; ANTISICKLING AGENT;

ANALGESIA; DISEASE DURATION; DIZZINESS; DRUG EFFICACY; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; INCIDENCE; LENGTH OF STAY; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PAIN INTENSITY; PAIN SEVERITY; PAINFUL SICKLE CELL DISEASE; PATHOGENESIS; PATIENT SATISFACTION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICKLE CELL ANEMIA; SYMPTOM; SYSTEMATIC REVIEW; ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; COMPLICATION; META ANALYSIS; PRESCHOOL CHILD;

ADOLESCENT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; HUMANS; PAIN; PIRACETAM; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84969560063     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006111.pub3     Document Type: Review

References (34)

1. Alvim RC, Viana MB, Pires MA, Franklin HM, Paula MJ, Brito AC, et al. Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease. Acta Haematologica 2005;113(4):228-33.
2. Viana MB, Alvim RC. Painful crises in children with sickle cell disease are not prevented by piracetam. Acta Haematologica 2009; Vol. 121, issue 1:9-10.
3. El-Hazmi M, Al-Fawaz I, Warsy A, Opawoye A, Taleb H, Howsawi Z, et al. Piracetam for the treatment of sickle cell disease in children - a double blind test. Saudi Medical Journal 1998;19(1):22-7.
4. El-Hazmi MA, Warsy AS, Al-Fawaz I, Farid M, Refai S, Opawoye AO, et al. Piracetam in the treatment of sickle cell disease [abstract]. The National Sickle Cell Disease Program Annual Meeting Conference Proceedings; 1995 March. 1995:162.
5. El-Hazmi MA, Warsy AS, Al-Fawaz I, Opawoye AO, Abu Taleb H, Howsawi Z, et al. Piracetam is useful in the treatment of children with sickle cell disease. Acta Haematologica 1996;96(4):221-6.
6. Mikati MA, Solh HM, Deryan DE, Sahli IF, Dabbous IA. A preliminary report on piracetam in sickle cell anemia: a double-blind crossover clinical trial and effects on erythrocyte survival. The King Faisal Specialist Hospital Medical Journal 1983;3(4):233-6.
7. De Araujo JT, Nero GS. Piracetam and acetamide in sickle-cell disease. Lancet 1977;2(8034):411.
8. De Melo GO. Piracetam in sickle cell anaemia. Lancet 1976;2(7995):1139.
9. Franklin IM. Piracetam in sickle cell disease. Lancet 1980;1(8143):767.
10. Gini EK, Sonnet J. Use of piracetam improves sickle cell deformability in vivo. Journal of Clinical Pathology 1987;40(1):99-102.
11. Sonnet J, Gini EK, Cornu G. Trial prevention of vaso-occlusive crises in homozygote in sickle cell anemia using piracetam [Essai de prevention des crises vaso-occlusives de la drepanocytose homozygote par le piracetam]. Annales de la Société belge de médecine tropicale 1985;65(1):77-84.
12. Al-Arrayed SS, Haites N. Features of sickle-cell disease in Bahrain. Eastern Mediterranean Health Journal 1995;1(1):112-9.
13. Asakura T, Ohnishi ST, Adachi K, Ozguc M, Hashimoto K, Devlin MT, et al. Effect of piracetam on sickle erythrocytes and sickle hemoglobin. Biochimica et Biophysica Acta 1981;668(3):397-405.
14. Balkaran B, Char G, Morris JS, Serjeant BE, Serjeant GR. Stroke in a cohort study of patients with homozygous sickle cell disease. Journal of Pediatrics 1992;120(3):360-6.
15. Brozovic M, Davies SC. Management of sickle cell disease. Postgraduate Medical Journal 1987;63(742):605-9.
16. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood 1994;84(2):643-9.
17. Davies SC, Oni L. The management of patients with sickle cell disease. BMJ 1997;315(7109):656-60.
18. Davies EG, Riddington C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: ]
19. de Araujo JT, Nero GS. Piracetam and acetamide in sickle-cell disease. Lancet 1977;2(8034):411.
20. El-Hazmi MA, Bahakim HM, al-Swailem AM, Warsy AS. The features of sickle cell disease in Saudi children. Journal of Tropical Pediatrics 1990;36(4):148-55.
21. El-Hazmi MAF, Warsy AS, Al Momen AK, Harakati M. Hydroxyurea for the treatment of sickle cell disease. Acta Haematologica 1992;88(4):170-4.
22. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
23. Goldberg CAJ. A new method for starch gel electrophoresis with special reference to the determination of hemoglobin A2. Clinical Chemistry 1958;4:484.
24. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library. The Cochrane Collaboration. Chichester, UK: John Wiley & Sons, Ltd; 2005, Issue 3. 2005.
25. Jones AP, Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: ]
26. Knight S, Singhal A, Thomads P, Serjeant GR. Factors associated with lowered intelligence in homozygous sickle cell disease. Archives of Disease in Childhood 1995;73(4):316-20.
27. Moriau M, Crasborn L, Lavenne-Pardonge E, von Frenckell R, Col-Debeys C. Platelet anti-aggregant and rheological properties of piracetam. A pharmacodynamic study in normal subjects. Arzneimittelforschung 1993;43(2):110-8.
28. National Institutes of Health. National Heart, Lung and Blood Institute. The Management of Sickle Cell Disease. NIH Publication No. 02-2117. 4th 2002.
29. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
30. Serjeant GR. The geography of sickle-cell disease: opportunity for understanding its diversity. Annals of Saudi Medicine 1994;14:237-46.
31. Serjeant GR, Serjeant BE. Sickle Cell Disease. 3rd Edition. Oxford: Oxford University Press, 2001.
32. Topley JM, Rogers DW, Stevens MC, Serjeant GR. Acute splenic sequestration and hypersplenism in the 5 years of life in homozygous sickle cell disease. Archives of Disease in Childhood 1981;56(10):765-9.
33. Vernon MW, Sorkin EM. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs and Aging 1991;1(1):17-35.
34. World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. www.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 15 February 2006).